Oncimmune to publish full year results on 30th October 2020

Oncimmune Holdings plc (LON:ONC), the leading global immunodiagnostics group, will be announcing its full year results for the year ended 31 May 2020 on Friday, 30 October 2020.

Adam Hill, Chief Executive Officer, together with Matthew Hall, Chief Financial Officer, will host a presentation and conference call for analysts at 11:30am GMT on the day of the results.

For conference call details please contact Alexander Davis of FTI Consulting at Alexander.Davis@fticonsulting.com or 020 3727 1000.

The management team will also host on Investor Meet Company a live presentation of the results on Friday, 30 October at 15:00 GMT.

• The online presentation will be open to all existing shareholders and potential new investors.

• Questions can be submitted before the event via your Investor Meet Company dashboard or at any time during the live presentation via the “Ask a Question” function. Responses to the Q&A will be published at the earliest opportunity on the Investor Meet Company platform.

• Investor feedback can also be submitted directly to management immediately following the event.

Access to Investor Meet Company is free and interested parties can register to attend the presentation via the following link: https://www.investormeetcompany.com/essensys-plc/register-investor

Attendees who have already registered on the Investor Meet Company platform to meet the Company will automatically receive an invitation to the presentation.

Click to view all articles for the EPIC: ONC
Or click to view the full company profile:

Oncimmune signs agreement with major cancer center, Dana-Farber Cancer Institute

23rd July 2021

Oncimmune Holdings plc (LON:ONC), the leading global immunodiagnostics group, has announced it has signed an autoantibody profiling contract with Dana-Farber Cancer Institute in Boston, Massachusetts. Dana-Farber, a clinical affiliate and research institute of Harvard Medical School,

Oncimmune FY21 revenues in line with market expectations

8th June 2021

Oncimmune Holdings plc (LON:ONC), the leading global immunodiagnostics group, has provided a trading update for the 12 months ended 31 May 2021. The Company expects to announce its FY21 results in late September 2021. FY21 revenues

Oncimmune: Reacquisition of IP and distribution rights for Chinese lung cancer test

5th May 2021

Oncimmune Holdings plc (LON:ONC) has reacquired IP and distribution rights for its lung cancer diagnostic (EarlyCDT®) that has been recalibrated for enhanced accuracy in Asian populations. Trials are due to complete in H1 2021, with regulatory

Oncimmune acquires China rights to EarlyCDT product portfolio

5th May 2021

Oncimmune Holdings plc (LON:ONC), the leading global immunodiagnostics group, has announced that it has successfully agreed to acquire the intellectual property and distribution rights for the EarlyCDT® technology in the People’s Republic of China and Hong Kong from Genostics

Oncimune signs agreements with Roche and Cedars-Sinai to profile patients using their novel Infectious Disease panel

6th April 2021

Oncimmune Holdings plc (LON:ONC), the leading global immunodiagnostics group, has announced that it has signed two separate agreements with Roche Pharmaceuticals and Cedars-Sinai Medical Center, in each case to use the Company’s newly developed and proprietary

Oncimmune experience a sixfold increase in revenue against the same period last year

15th February 2021

Oncimmune Holdings plc (LON:ONC), the leading global immunodiagnostics group, has announced its interim results for the six months ended 30 November 2020. Commercial highlights Services – ImmunoINSIGHTS · Marked increase in commercial activity as large pharmaceutical and

Oncimmune publication of autoantibody profiles for response prediction to Rheumatoid Arthritis treatment

15th December 2020

Oncimmune Holdings plc (LON:ONC), the leading global immunodiagnostics group, has announced the publication by PLOS ONE of a study, supported by the Oncimmune’s ImmunoINSIGHTS team, which analysed autoantibodies in patients with newly diagnosed Rheumatoid Arthritis (RA) who were

Oncimmune signs commercial contract to supply its EarlyCDT Lung blood test to NHS Norfolk & Waveney

14th December 2020

Oncimmune Holdings plc (LON:ONC), the leading global immunodiagnostics group, has announced that it has signed a commercial contract to supply its EarlyCDT Lung blood test to NHS Norfolk & Waveney Clinical Commissioning Group. Additionally, the Company

Oncimmune “another opportunity to enrich and validate its capabilities” says Zeus Capital

12th November 2020

Oncimmune Holdings plc (LON:ONC) has entered a commercial partnership with US West Coast biotech, Augmenta Bioworks, to profile patient plasma samples and characterise antibody therapeutic candidates discovered via Augmenta’s proprietary discovery platforms. There is an option

Oncimmune signs new master service agreement with Augmenta

11th November 2020

Oncimmune Holdings plc (LON:ONC), the leading global immunodiagnostics group, has announced that it has signed a new master service agreement with Augmenta Bioworks, Inc. to profile patient plasma samples and characterise therapeutic candidates discovered through Augmenta’s

Oncimmune AGM to be held 30th November 2020

9th November 2020

Oncimmune Holdings plc (LON:ONC), the leading global immunodiagnostics group, has given notice that its Annual General Meeting will be held at 10:00 am on 30 November 2020 at the offices of Zeus Capital, 10 Old Burlington Street,

Oncimmune “outlook for the services business appears increasingly optimistic” says Zeus Capital

2nd November 2020

Oncimmune Holdings plc (LON:ONC) FY 2020 was the first full year of delivery under Oncimmune’s three-year plan of operational, technical and commercial targets for products and services, accomplishing major milestones to support their commercialisation, accelerating post

Oncimmune deliver a step-change in revenue growth

30th October 2020

Oncimmune Holdings plc (LON:ONC), the leading global immunodiagnostics group, has announced its unaudited results for the year ended 31 May 2020 and provides an update on recent progress. Highlights Commercial progress EarlyCDT® Lung – Strategic commercialisation agreement signed

Clinical study initiated by Biodesix to further support adoption of Oncimmune’s EarlyCDT® Lung in US market

28th October 2020

Oncimmune Holdings plc (LON:ONC), the leading global immunodiagnostics group, has noted the initiation of a study by Biodesix Inc using Oncimmune’s EarlyCDT® Lung blood test, which is marketed in the US by Biodesix as Nodify CDTTM. Biodesix

Oncimmune EarlyCDT lung blood test data presented to CHEST Annual Meeting 2020

21st October 2020

Oncimmune Holdings plc (LON:ONC), the leading global immunodiagnostics group, has noted that recently published data from two clinical studies using Oncimmune’s EarlyCDT® Lung blood test, which is marketed in the US by Biodesix Inc. as Nodify CDTTM, confirmed

Oncimmune signs COVID-19 antibody profiling commercial agreement with Cedars-Sinai

13th October 2020

Oncimmune Holdings plc (LON:ONC), the leading global immunodiagnostics group, has announced that, following its announcement on 6 October that Oncimmune is being funded by the UK Government to develop a COVID-19 biomarker panel, the Company has

Advanced Oncotherapy: Progress towards commissioning of first LIGHT

8th October 2020

Advanced Oncotherapy plc (LON:ONC) goal is to deliver an affordable and novel PT system, called LIGHT, based on state-of-the-art technology developed originally at the world-renowned CERN. Over the past two years, the project has been significantly

Oncimmune “COVID-19 NavigAID panel participation enhances the investment case” says Zeus Capital

7th October 2020

The award of funding to Oncimmune Holdings plc (LON:ONC) by the ‘UK Research and Innovation Ideas to Address COVID-19’ project, leverages its proprietary ImmunoINSIGHTS technology to help in predicting disease severity and treatment response, in collaboration

Be sure to check our sister interview main ratings news website